Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2025 06:30 ET | Source: Mural Oncology, Inc.

Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis Continued demonstration of favorable tolerability...
March 11, 2025 16:01 ET | Source: Mural Oncology, Inc.

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025 Top-line data readout of...
February 18, 2025 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies...
January 09, 2025 16:00 ET | Source: Mural Oncology, Inc.

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary...
December 03, 2024 16:15 ET | Source: Mural Oncology, Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
November 20, 2024 16:15 ET | Source: Mural Oncology, Inc.

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily...
November 13, 2024 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025...
November 11, 2024 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology to Participate in Two Upcoming Investor Conferences

WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
November 07, 2024 16:15 ET | Source: Mural Oncology, Inc.

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune...
November 04, 2024 16:15 ET | Source: Mural Oncology, Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...